Reversible exacerbation of obstructive sleep apnea by α1-adrenergic blockade with tamsulosin: A case report  by Moran, Mark
lable at ScienceDirect
Respiratory Medicine Case Reports 19 (2016) 181e186Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate/rmcrReversible exacerbation of obstructive sleep apnea by a1-adrenergic
blockade with tamsulosin: A case report
Mark Moran
55 Orinda View Rd, Orinda, CA 94563, United Statesa r t i c l e i n f o
Article history:
Received 26 August 2016
Received in revised form
18 September 2016
Accepted 6 October 2016
Keywords:
AHI
CPAP
Obstructive sleep apnea
Prostatic hypertrophy
Tamsulosin
Alpha-adrenergic antagonistE-mail address: mark@moranadvisors.com.
http://dx.doi.org/10.1016/j.rmcr.2016.10.005
2213-0071/© 2016 The Author. Published by Elsevier La b s t r a c t
Obstructive sleep apnea (OSA) is characterized by repeated involuntary closure of the pharyngeal
airspace during sleep. Normal activity of the genioglossus (GG) muscle is important in maintaining
airway patency, and inhibition of GG activity can contribute to airway closure. Neurons in the hypoglossal
motor nucleus (HMN) regulate GG activity. Adrenergic tone is an important regulator of HMN neuronal
excitability. In laboratory models a1-adrenergic antagonists inhibit HMN neurons and GG activity, sug-
gesting that a1-adrenergic antagonism might adversely affect patients with OSA. To date there has been
no report of such a case. Case Summary: The patient was a 67-year old man with a 27-month history of
obstructive sleep apnea. Diagnostic polysomnography demonstrated a baseline apnea-hypopnea index
(AHI) of 21.3 and a trough oxygen saturation of 84%. Treatment with continuous positive airway pressure
(CPAP) was initiated. The AHI in year 1 averaged 1.0 ± 0.1 (mean ± SD) and 0.8 ± 0.1 in year 2. Other
medical conditions included hypertension controlled with losartan and benign prostatic hypertrophy not
well controlled by ﬁnasteride monotherapy. The a1-adrenergic receptor antagonist tamsulosin 0.4 mg
daily was added. Shortly after initiation of tamsulosin, subjective sleep quality deteriorated. Signiﬁcant
surges in obstructive events, apneic episodes, and AHI were also recorded, and nocturnal airway pressure
was frequently sustained at the CPAP device maximum of 20 cm H2O. Tamsulosin was discontinued. CPAP
parameters and sleep quality returned to the pre-tamsulosin baselines within 10 days. These ﬁndings
suggest that a1-adrenergic blockade with tamsulosin may exacerbate sleep-disordered breathing in
susceptible patients.
© 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obstructive sleep apnea (OSA) is a common and sometimes
serious disorder, affecting an estimated 20e30% of men and
10e15% of women [1e3]. It is characterized by recurrent collapse of
the oropharyngeal musculature during sleep, leading to partial or
complete obstruction of the upper airway [4]. These changes are
most pronounced during rapid eye movement (REM) sleep, when
skeletal muscle tone reaches its lowest point, resulting in reduced
genioglossus (GG) and intercostal muscle tone and increased sus-
ceptibility to upper airway obstruction. Remmers and colleagues
provided some of the earliest clinical evidence that GG muscle
relaxation is involved in the pathophysiology of obstructive sleep
apnea [5]. Several groups have investigated the neuroanatomy and
control of GG activity during both sleep and wakefulness,td. This is an open access article udemonstrating that neurons in the hypoglossal motor nucleus
(HMN) regulate GG activity [4,6e15].
The work of Horner's group in Toronto is of particular relevance
to the case presented in this paper. He and his colleagues have
developed a model of freely-moving, instrumented rodents well-
suited for examining the pharmacological manipulation of HMN
function. Adding to other work [16,17], they have recently
demonstrated the effects on respiratory muscle activity of stimu-
lation and blockade of HMN a1-adrenergic receptors [12]. Micro-
dialysis perfusion with the a1-adrenergic agonist phenylephrine
increased HMN neuronal and GG activity while perfusion with the
a1-antagonist terazosin markedly decreased both. These agonistic
and antagonistic effects were demonstrated during both wakeful-
ness and sleep.
Alpha1-adrenergic antagonists are in common clinical use.
Adverse respiratory effects in patients with OSA, including that of
reversible airway obstruction, have not been reported to date. In
the current case, a patient with stable OSA treated with CPAPnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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benign prostatic hypertrophy (BPH). Tamsulosin dosing was asso-
ciated with a rapid increase in both the number and severity of
symptomatic episodes of airway obstruction. These changes
reversed upon discontinuation of the drug.
2. Case
A 67-year old male with a 27-month history of obstructive
sleep apnea treated with CPAP presented to the clinic with com-
plaints of fatigue and a marked deterioration of subjective sleep
quality, changing as the patient said from “fairly good” to “now
very bad”. The adverse changes had begun approximately four
weeks prior to the clinic visit, with a marked deterioration re-
ported for the most recent seven days. His only other complaint
was mild constipation, also beginning during the previous month.
The patient had continued his usual professional activities as a
physician, although he felt “much less efﬁcient than usual.” The
patient typically used CPAP between the hours of 11:00 p.m. and
6:00 a.m. He was not a shift worker. He traveled frequently for
work, usually involving 3e9 h changes in time zones. He used
CPAP during overnight ﬂights. There had, however, been no air
travel during the four weeks prior to the clinic visit. He continued
to exercise daily. There were no known infectious exposures. He
continued to report that he did not smoke, consume alcohol,
ingest herbal or natural-product remedies such as yohimbine [18]
or use illicit drugs.
Physical examination revealed an alert, mildly fatigued man in
no acute distress. Vital signs and the remainder of his examination
were normal for his age. In particular, the cardiopulmonary ex-
aminationwas unremarkable. Therewere no pulmonary or tracheal
adventitial breath sounds. The ear/nose/throat examination was
also unchanged from his initial presentation (described further
below). His weight was 65 kg and BMI 21.8 kg/m2. His weight had
decreased gradually over 18 months from a peak of 77 kg. Most but
not all of the weight loss was described by the patient as voluntary.
Epworth Sleepiness Scale (ESS) was 4.
Other medical conditions and medications included:
 hypertension for 6 years treated with losartan 100 mg daily
 gastroesophageal reﬂux for 1 year treated with ranitidine
300 mg daily
 prostatic hypertrophy for 13 years treated for the most recent
nine months with ﬁnasteride 5 mg daily to which tamsulosin
0.4 mg daily had been added four weeks before the clinic visit
(and which resulted in a 40% increase in peak urinary ﬂow rate
after three weeks of dosing)2.1. Past sleep history
The patient originally presented with symptoms of insomnia
and severe nocturnal diaphoresis. At initial presentation, the pa-
tient's physical examinationwas noteworthy for a slight left inferior
nasal septal deviation, a high/narrow hard palate, Mallampati
score ¼ 4, class 2 malocclusion with 4 mm overjet, and retro-
gnathia. Diagnostic polysomnography demonstrated an AHI of 21.3,
trough oxygen saturation of 84%, oxygen desaturation index of 7.0,
and Periodic Limb Movement Index of 45.6. The patient did not
report symptoms of restless leg syndrome. There was no other
known sleep disorder.
He began empiric CPAP (Resmed® Auto S-9, Rescan™ software
Version 5.6.0.9419). The CPAP prescription was then adjusted
monthly over the ensuing four months based on detailed
outpatient data downloads. The patient reported symptomaticimprovement beginning approximately six months after initia-
tion of CPAP. Repeat polysomnography was declined. Minor al-
terations in CPAP settings were made periodically in an effort to
improve patient comfort. Regular follow-up visits demonstrated
excellent compliance (98% in year 1 and 97% in year 2 and
beyond).
His CPAP prescription on presentation for the current clinic visit
had been unchanged for more than six months: auto-PAP
12.6e20 cm H2O (1.24e1.96 kPa) with an EPR (expiratory pres-
sure relief) of 1 cm H2O (0.098 kPa). There was a 5-min linear
pressure ramp to the target minimum from a starting airway
pressure of 7 cm H2O (0.69 kPa).
2.2. CPAP data
CPAP unit data were available for approximately two years with
approximately 85% of nights also having detailed data available.
Both detailed and summary data were recorded for all nights dur-
ing the nine months immediately preceding the clinic visit. During
the one-year period preceding the clinic visit (months 16e27 after
the formal diagnosis of OSA), AHI averaged 0.8 ± 0.1 (mean ± SD),
AI ¼ 0.1, HI ¼ 0.7. The maximal single-night values recorded during
this same one-year period were AHI ¼ 2.7, AI ¼ 0.9, and HI ¼ 2.2
(not all occurring on the same night). The patient's data for AHI and
AI for the three months immediately prior to the tamsulosin dosing
period, the period of tamsulosin dosing, and one month after
discontinuation appear in Fig. 1.
On a night-to-night basis, airway obstruction varies in patients
with OSA [19]. Although the variability in the current patient's data
appears to be greater during the on-tamsulosin period, the coefﬁ-
cient of variation is actually similar in both the on- and off-periods
(on ¼ 1.6 vs off ¼ 1.3). Notwithstanding this similarity, during the
119 off-tamsulosin days of Fig. 1 AI did not exceed 0.9. Phrased in
another way, AI exceeded 0.9 on 0 of 119 days. (A review of his-
torical data showed that AI had not exceeded 0.9 in more than 450
days.) During the on-tamsulosin days in Fig. 1B, AI exceeded the
previous 18months' maximum on 9 of 34 days. The probability that
this ﬁnding regarding days in excess of the prior AI maximum (0 of
119 days vs. 9 of 34 days) is due to chance alone is less than 1 108
(chi-square, Microsoft® Excel® v14.6.8).
The events during tamsulosin exposure were obstructive rather
than central in origin (Fig. 2).
During the three months preceding initiation of tamsulosin, the
patient experienced a total of 93 recorded events (9 obstructive, 84
central). During the approximately one month (34 days) of tam-
sulosin exposure, the patient experienced 281 events (240
obstructive, 41 central). In the month following discontinuation of
tamsulosin there were 62 events recorded (9 obstructive, 53 cen-
tral). The probability that this increase in both the number and
proportion of obstructive events during tamsulosin exposure
occurred at random is less than 1  1010 (chi-square).
While the absolute values of AHI and AI may appear to be
numerically modest, the increased frequency and duration of
obstructive events resulted for this patient in both disturbed sleep
and compromised cognition. Moreover, the incidence and severity
of symptomatic obstruction appeared to be increasing with
continued tamsulosin dosing.
More detailed evidence of airway obstruction for the night of
the peak AI, and which then resulted in the immediate, next-
morning termination of tamsulosin, is shown in Fig. 3.
Before the initiation of tamsulosin therapy, and from the more
than 700 nights of detailed historical CPAP data available for this
patient, the combination of persistent high-frequency obstructive
events and sustained maximal elevation in airway pressure shown
had never been observed.
Fig. 1. Values for AHI (panel A) and AI (panel B) are shown by night in monthly intervals before and after tamsulosin exposure (“off tamsulosin”, blue dashes) and during tamsulosin
exposure (“on tamsulosin”, AHI solid red diamonds, AI solid red circles). The on-tamsulosin data points begin with the ﬁrst dose of tamsulosin and, to accommodate the time
needed to clear tamsulosin from the body, continue until four days after the ﬁnal tamsulosin dose. As shown, both AHI and AI had been low and stable for months prior to the
initiation of dosing with tamsulosin. Within two days after the ﬁrst dose of tamsulosin, both AHI and AI exceeded values that had not been exceeded for months. Both AHI and AI
reached apex values just before tamsulosin dosing was terminated speciﬁcally because of these changes and attendant symptoms. After termination of tamsulosin, AHI and AI
declined over several days, returning to and then remaining at pre-tamsulosin levels (During the ﬁve calendar months shown in Fig. 1, the patient used CPAP for a total of
1064:06 h:min, for an average of 6 h 57 min per night, >4 h per night on 153 nights, <4 h per night on 0 nights.). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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The current case report appears to be the ﬁrst to document a
reversible deterioration in the signs and symptoms of OSA
following systemic a1-adrenergic blockade. The incidence of OSA
and its associated morbidity and mortality are signiﬁcant [1e3,20].
An estimated four million men in the United States who have BPH
(6% of men over 40) receive one of the a1-adrenergic blockers
[21,22]. If these two disorders segregate independently, then there
could readily be some 200,000 men in the U.S. with OSA and BPH
who are also receiving an a1-adrenergic antagonist. Some of these
OSA patients will not be treated with CPAP. As a result, the OSA-
CPAP/BPH-a1-antagonist subset is probably smaller in number and
may explain how previous cases - if any - could have been missed.
On the other hand, any worsening of sleep quality in patients maynot be reported or could be attributed to other more common
causes.
From an examination of the current patient's data, increased
airway obstruction began to appear shortly after tamsulosin dosing
was initiated. The half-life of tamsulosin is approximately 15 h [23].
Standard pharmacokinetic-pharmacodynamic modeling [24,25]
would suggest that three or more days of dosing could be
required to achieve peak steady-state plasma levels of tamsulosin
and a similar period of time to eliminate the drug from circulation.
Even if peak levels required several days to establish in the current
patient, with continued tamsulosin dosing there was a trend to-
ward progressively higher values in the patient's AHI and AI. This
suggests the possibility of an increased pharmacodynamic airway
response developing over several weeks. The same type of obser-
vation e a progressively greater response to tamsulosin during
Fig. 2. The number of central events (panel A) and obstructive events (panel B) by night in monthly intervals before and after tamsulosin exposure (“off tamsulosin”, blue dashes)
and during tamsulosin exposure (“on tamsulosin”, solid red diamonds [central events] or solid red circles [obstructive events]). The on-tamsulosin data points begin with the ﬁrst
dose of tamsulosin and, to accommodate the time needed to clear tamsulosin from the body, continue until four days after the ﬁnal tamsulosin dose. The incidence of central events
did not change with a1-adrenergic blockade while both the incidence and duration (not shown) of obstructive events increased markedly during tamsulosin exposure. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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patients with prostatic hypertrophy [23]. Up to eight weeks of
dosing were required to achieve maximal clinical increases in uri-
nary ﬂow rates. Such pharmacodynamic response data also suggest
that adverse airway effects could still be observed during the ﬁrst
few days after the ﬁnal tamsulosin dose, after whiche if tamsulosin
were cause of increased airway obstruction - CPAP data would then
return to pre-tamsulosin values. This was the pattern observed in
the current patient.
There are multiple marketed a1-adrenergic antagonists,
differing in speciﬁcity, receptor afﬁnity and probably in blood-
brain-barrier permeability [26]. When adjusted for clinical dose,
however, pharmacological effects appear more uniform across the
class, at least for indicated uses. Tamsulosin, though, is a drug that
partitions into the brain (at least in some species) [27], has high a1-
receptor speciﬁcity and afﬁnity [26,28], a slow offset from its re-
ceptor [29], a prolonged half-life in older patients [23], and reducedclearance in some patients who concomitantly receive, as the cur-
rent patient did, an H2-antagonist like ranitidine [23]. These
pharmacological characteristics of tamsulosin, and perhaps the
concomitant use of ranitidine, may substantially account for the
observations in the current case.
While the preceding drug-speciﬁc considerations support a role
for tamsulosin in precipitating the respiratory compromise
observed in this patient, it is appropriate to ask if there were also
patient-speciﬁc contributory factors. There is adrenergic genetic
variation of relevance to OSA. However, it is a polymorphism in the
b1-, and not the a1-, adrenergic receptor that has been identiﬁed as
important, at least in those patients who also have - like the patient
of this report - hypertension [30]. In addition, the current patient's
BMI had decreased meaningfully from approximately 25 to 21
while on CPAP during the 18 months preceding the initiation of
tamsulosin therapy. A signiﬁcant weight loss in an OSA patient
beginning with a normal-range BMI could perhaps unfavorably
Fig. 3. Detailed CPAP device data output (ResScan™) from 25 November 2015 after what proved to be the ﬁnal dose of tamsulosin on the evening of 24 November 2015. Data
collection began at 00:15 a.m. and ended at 06:39 a.m., a total of 6 h 24 min. Airway pressure was maintained at the machine maximum of 20 cm H2O (1.96 kPa*) for approximately
3h 20 min (52% of the total data collection time). Median leak rate for the night was 9.6 L/min. Leak exceeded 24 L/min for fewer than 20 min. AHI peaked at 23 events/h, almost
entirely due to episodes of obstruction (red arrows), each obstructive event lasting 10e46 s, with the majority lasting 25 s or longer. Note that when the obstructive event rate was
at its highest, between 04:15 and 06:39 a.m., the leak rate was near its lowest for the night. [*Multiply cm H2O by 0.098 to convert to kPa.].
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any sensitivity to adverse muscular effects from a1-adrenergic
blockade may have been increased.
The strengths of this report include the availability of extensive
and detailed data: longitudinal clinical recordings of airway pres-
sures, ﬂows, and obstructive events from hundreds of nights pre-
ceding initiation of a1-adrenergic blockade with tamsulosin and
similarly detailed data during and after tamsulosin exposure. The
observed pattern of airway obstruction in this patient (onset,
worsening, and offset) ﬁt well with known tamsulosin pharmaco-
kinetics. Finally, preclinical data from multiple laboratories haveidentiﬁed a1-adrenergic blockade as a plausible mechanism for
interference with genioglossus activity and consequential airway
obstruction.
Potential weaknesses of the report include the absence of clin-
ical reports for other drugs in the same class and the unavoidable
fact that data from laboratory models cannot substitute for their
clinical counterparts. Whether a second polysomnography could
have yielded probative data for this patient that would have altered
the apparent response to tamsulosin is, of course, unknown.
It is very unlikely that the reversible obstruction observed in this
patient occurred at random. The only known pharmacological
M. Moran / Respiratory Medicine Case Reports 19 (2016) 181e186186changes were tamsulosin administration and withdrawal. The
clinical changes were consistent with preclinical observations. The
onset and offset of adverse respiratory effects were compatibly
timed with tamsulosin exposure. The statistics are familiar, simple,
and robust. In brief, one month's exposure to the a1-adrenergic
antagonist tamsulosin was associated with a reversible deteriora-
tion in the signs and symptoms of obstructive sleep apnea.
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